EvoGenix gets $1.6 million research grant

By Elaine Rigoli

Tampa, Fla., July 5 - EvoGenix Ltd. has been offered a grant of $1.66 million to fast track development of its anticancer antibody DMF10.

The grant will be provided over two years under the Australian government's commercial ready program, a merit-based grant program supporting product research and development.

EvoGenix said DMF10 is a hamster antibody, which has shown strong evidence of activity against lung cancer and melanoma.

The antibody attacks a structure on the surface of cancer cells that is not found on normal cells, creating a cancer therapy that is potentially both effective and devoid of side-effects.

EvoGenix said it is using its proprietary technologies to develop a highly active form of the antibody that can be tested in humans and will not be rejected when used to treat cancer patients.

DMF10 was in-licensed by EvoGenix from the University of Massachusetts in April 2006.

EvoGenix is an antibody therapeutics company based in Sydney, Australia.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.